INTRODUCTION
============

Recently, vitamin D has been studied as an important factor in the development of many diseases, and its importance is not limited to its classic role in bone health. Many previous works have shown an association between vitamin D deficiency or insufficiency and many disease like cardiovascular disease[@b1-jomes-27-053],[@b2-jomes-27-053], cancer[@b3-jomes-27-053],[@b4-jomes-27-053], and infection.[@b5-jomes-27-053] The relationship between vitamin D levels and the development of type 2 diabetes mellitus[@b6-jomes-27-053]--[@b8-jomes-27-053] and metabolic syndrome[@b9-jomes-27-053]--[@b11-jomes-27-053] has also been a recent focus and many studies have reported that low vitamin D levels are associated with insulin resistance and the onset of metabolic syndrome.

Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease of liver associated with insulin resistance. NAFLD is a common condition among patients with type 2 diabetes and according to a meta-analysis reported in 2016, its comorbidity with type 2 diabetes is about 22.51%.[@b12-jomes-27-053] The presence of NAFLD in type 2 diabetes can increase the incidence of vascular complications including cardiovascular disease.[@b13-jomes-27-053],[@b14-jomes-27-053] Previous studies have shown that lower levels of vitamin D may contribute to NAFLD and abdominal obesity.[@b10-jomes-27-053],[@b15-jomes-27-053]--[@b17-jomes-27-053] Furthermore, the negative effect of low vitamin D levels on insulin resistance and vascular complications of type 2 diabetes has recently been suggested.[@b18-jomes-27-053]--[@b20-jomes-27-053] Still, the underlying mechanism for the association between vitamin D levels and NAFLD is not entirely known and more human research is needed. In this study, we evaluated NAFLD and abdominal fat accumulation according to vitamin D status in patients with type 2 diabetes.

METHODS
=======

Subjects
--------

Data from patients with type 2 diabetes who visited the diabetes clinic at Soonchunhyang University Bucheon Hospital from 2011 to 2014 were analyzed retrospectively. Patients with type 2 diabetes (n=995) who underwent regular outpatient clinic follow-up for more than 2 years were included. The following patients were excluded: (1) patients (n=378) in whom abdominal ultrasonography was not performed, (2) those (n=92) who were taking calcium, vitamin D supplementation or osteoporosis therapies or had uncontrolled thyroid or parathyroid disease, (3) those (n=120) in whom serum vitamin D levels were not measured, and (4) those (n=103) who had other chronic liver diseases, any viral hepatitis patients and viral carriers, hemochromatosis patients, any hepatic malignancy patients and alcoholic liver disease patients or heavy alcohol drinkers (more than 140 g/wk of pure alcohol).

The remaining 302 patients with type 2 diabetes were ultimately included. We used patient medical records to carefully review their demographic and biochemical data. This study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital (IRB No. 2017-10-020). The informed consent was exempted from the Institutional Review Board because this study is a retrospective and analytical study.

Laboratory biomarker measurements
---------------------------------

Laboratory biomarkers measured included fasting glucose, glycated hemoglobin (HbA1c), C-peptide, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine. Ion-exchange high-performance liquid chromatography (Bio-Rad, Hercules, CA, USA) was used to measure HbA1c. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: fasting insulin (μIU/mL)×fasting plasma glucose (mg/dL)/405.

The vitamin D status was evaluated by measuring the level of 25-hydroxyvitamin D (25(OH)D), a commonly used marker for vitamin D status. 25(OH)D concentration was measured using a radioimmunoassay (CIS Bio International, Paris, France). Patients were divided into three groups according to their 25(OH)D levels: the vitamin D deficient group (n=116, 25(OH)D \<10 ng/mL), the vitamin D insufficient group (n=118, 10 ng/mL≤25(OH)D \<20 ng/mL) and the vitamin D sufficient group (n=68, 25(OH)D ≥20 ng/mL). Cutoff levels for vitamin D status were as defined in the World Health Organization guidelines and by the Institute of Medicine.[@b21-jomes-27-053],[@b22-jomes-27-053]

Abdominal fat and NAFLD assessment
----------------------------------

Ultrasonography was used to assess visceral fat thickness (VFT) and abdominal subcutaneous fat thickness (SFT). The distance between the posterior aspect of the rectus abdominis muscle and the anterior wall of the aorta was defined as VFT[@b23-jomes-27-053] and the maximal thickness of the fat tissue layer from the skin-fat interface to the linea alba was defined as SFT. A single experienced investigator measured abdominal fat thickness using a high-resolution B-mode ultrasonography. The 3.5-MHz convex-array probe and a 12-MHz linear-array probe were used to measure VFT and SFT, respectively. The intraobserver technical measurement errors for VFT and SFT were between 1.4%--2.3% and 1.1%--1.7%, respectively. Skilled radiologists and gastroenterologists performed the abdominal ultrasonography. Hepatic steatosis was diagnosed based on characteristic sonographic features, i.e., diffuse hyper-echogenicity of the liver relative to the kidneys, vascular blurring and ultrasound beam attenuation.

Statistical analysis
--------------------

SPSS version 14.0 software (SPSS Inc., Chicago, IL, USA) was used to conduct the statistical analysis. Results are summarized with mean and standard deviation for continuous variables. Skewed distributed variables, like fasting glucose, HbA1c, AST, ALT and lipid profiles, were log-transformed and then analyzed. A chi-square test was performed to compare categorical variables. A student *t*-test was used to evaluate the significance of the mean differences including 25(OH)D levels in patients with and without NAFLD and in those without NAFLD. One-way analysis of variance was performed to evaluate the differences of means among groups according to the 25(OH)D levels. The correlation between serum 25(OH)D and clinical parameters was analyzed with Pearson or Spearman correlation analyses. Multivariate logistic regression was performed to determine the odds ratios (ORs) for NAFLD after adjusting for other variables. *P*-values less than 0.05 were considered as statistically significant.

RESULTS
=======

The prevalences of vitamin D deficient and vitamin D sufficient patients among patients with type 2 diabetes were 38.4% and 22.5%, respectively. The prevalence of NAFLD in all patients with type 2 diabetes included in the study was 62.9%. The mean levels of 25(OH)D were 21.7±14.1 ng/mL and 15.1±9.7 ng/mL in patients with type 2 diabetes with or without NAFLD, respectively (*P*=0.003).

The clinical and demographic characteristics of patients are described in [Table 1](#t1-jomes-27-053){ref-type="table"}. The mean ages of vitamin D deficient, vitamin D insufficient, and vitamin D sufficient groups were 59.1, 55.3, and 59.9 years. Body mass index (BMI) was not statistically different between the three groups (24.4±4.0 kg/m^2^ in the vitamin D deficient group, 24.8±4.2 kg/m^2^ in the vitamin D insufficient group, and 25.2±3.8 kg/m^2^ in the vitamin D sufficient group; *P*=0.378). Levels of fasting plasma C-peptide were significantly increased according to the increase in 25(OH)D (2.1±1.4 ng/mL in the vitamin D deficient group, 2.9±2.0 ng/mL in the vitamin D insufficient group, and 3.6±3.5 ng/mL in the vitamin D sufficient group, *P*=0.037). However, no statistical differences in serum fasting plasma glucose, HbA1c, lipid profiles, AST, ALT and HOMA-IR were found according to 25(OH)D status.

Serum 25(OH)D levels were positively correlated with systolic blood pressure, fasting C-peptide, and fasting insulin ([Table 2](#t2-jomes-27-053){ref-type="table"}). VFT was significantly higher in the vitamin D deficient group compared to in the vitamin D sufficient group (54.6 mm vs. 44.6 mm, *P*=0.001), but no differences in SFT were found to correlate with 25(OH)D status ([Fig. 1](#f1-jomes-27-053){ref-type="fig"}). The prevalence of NAFLD was significantly higher in the vitamin D deficient group compared to the vitamin D sufficient and vitamin D insufficient groups (75.0% vs. 36.4% vs. 64.0%, *P*=0.001) ([Fig. 2](#f2-jomes-27-053){ref-type="fig"}). In multivariate logistic analysis, after adjustment for age, sex, BMI, HbA1c, and HOMA-IR, ORs and 95% confidence intervals for NAFLD in both the vitamin D sufficient (0.109 \[0.035--0.342\], *P*\<0.001) and vitamin D insufficient groups (0.244 \[0.075--0.793\], *P*=0.019) were significantly lower than in the vitamin D deficient group ([Table 3](#t3-jomes-27-053){ref-type="table"}).

DISCUSSION
==========

According to the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV), vitamin D insufficiency is very common among Koreans.[@b24-jomes-27-053] In our cohort, only 22.5% of patients had serum vitamin D levels above 30 ng/mL. The results of our study suggest that low vitamin D levels are associated with NAFLD and abdominal visceral fat accumulation in Korean patients with type 2 diabetes. In this study, the lower prevalence of NAFLD among patients with higher levels of vitamin D remained significant even after adjusting for possible confounding factors like age, sex, BMI, HbA1c, and HOMA-IR. Some studies have also demonstrated the association between levels of vitamin D and the risk of NAFLD.[@b25-jomes-27-053],[@b26-jomes-27-053] Moreover, a recent study based on data from the U. S. Third National Health and Nutrition Examination Survey reported that vitamin D levels were associated with mortality from diabetes and Alzheimer disease in NAFLD.[@b27-jomes-27-053] A randomized prospective study consisting of 81 NAFLD patients showed that the addition of vitamin D along with lifestyle modification resulted in significant improvements in serum ALT and adiponectin levels. Because vitamin D is known to be involved in immune regulation, cell differentiation and proliferation, and inflammatory responses, low levels of vitamin D are thought to play a part in the pathogenesis of NAFLD by upregulating hepatic inflammation through adipocytokines.[@b28-jomes-27-053]

In our study, no differences in glycemic control, HOMA-IR, BMI, or abdominal SFT were found between groups with different 25(OH)D status. However, abdominal VFT was significantly higher in the vitamin D deficient group compared to the vitamin D sufficient group. Previous data has suggested that abdominal obesity is significantly associated with vitamin D deficiency.[@b16-jomes-27-053],[@b17-jomes-27-053] Cheng et al.[@b29-jomes-27-053] reported that lower vitamin D levels were associated with greater regional adiposity in the Framingham Heart Study. In a Malaysian study, vitamin D insufficiency was independently associated with greater abdominal obesity.[@b30-jomes-27-053] These studies reported that the association between vitamin D and visceral fat was more potent than with abdominal subcutaneous fat.

In this study, serum 25(OH)D levels were not correlated with glycemic control and HOMA-IR, but did correlate significantly with fasting C-peptide and insulin levels. Results from previous studies on the association between vitamin D deficiency and glycemic control and insulin resistance in patients with type 2 diabetes have been inconsistent.[@b31-jomes-27-053]--[@b34-jomes-27-053] The presence of vitamin D receptors on pancreatic β cells[@b35-jomes-27-053] and the presence of a vitamin D response element in the insulin gene[@b36-jomes-27-053] are suggested mechanisms for the effect of vitamin D on pancreatic β cells. A prospective study by Kayaniyil et al.[@b34-jomes-27-053] reported that higher vitamin D levels independently predicted better β-cell function in type 2 diabetes. However, a case-control study by Fondjo et al.[@b32-jomes-27-053] reported there was no association between vitamin D deficiency and insulin resistance or β cell function. These results are thought to be inconsistent due to differences in race, ethnicity, obesity and nutritional status. For our current study, since the participants were patients with type 2 diabetes, previous usage of oral hypoglycemic agents may have interfered with the HOMA-IR results.

Our current study has several limitations. First, since our study was designed to be cross-sectional, we could not determine the causal relationship between vitamin D levels and NAFLD and abdominal visceral fat accumulation. Second, due to the lack of data, we could not classify NAFLD by severity. Other possible important factors confounding the vitamin D levels, like outside activity, dietary habits and seasonal variations in vitamin D, were also not included in our study. Sex difference also is an important factor. Stadlmayr et al.[@b37-jomes-27-053] reported that vitamin D levels are independently associated with type 2 diabetes in women, but not in men. Verdoia et al.[@b38-jomes-27-053] also reported that lower vitamin D levels in women play a more relevant role in conditioning the severity of coronary artery disease than in men. Also, as previously known, sex is an important factor in the assessment of abdominal fat and NAFLD. However, in our current study, probably due to lack of data, we could not derive significant results from differences in sex. Nevertheless, we adjusted for sex difference in our multivariate logistic analysis of vitamin D and NAFLD. Due to lack of data, the above-mentioned factor including the sex difference should be investigated in a future study. Finally, since our study was based on a single clinical center, there is a possibility of selection bias on the results. Nonetheless, this single-center study also conferred a high degree of consistency with respect to laboratory data and the evaluation of NAFLD.

Despite these limitations, our study has strength in that the patients were divided into three groups based upon their vitamin D status, and the important metabolic variables in each group were compared and evaluated with each other group. Moreover, this study had a high degree of consistency with respect to laboratory data and the evaluation of NAFLD. The association of vitamin D with the development of many chronic diseases has been the focus of much research recently. The important role of vitamin D on the development of metabolic disease including NAFLD has been established, but many more studies are needed because the data are still incoherent. In this study, the vitamin D deficient group had a thicker VFT and higher NAFLD prevalence than either the vitamin D sufficient or vitamin D insufficient groups. Larger prospective studies will be required to elucidate the associations between vitamin D levels and NAFLD and abdominal fat in patients with type 2 diabetes.
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###### 

Clinical and demographic characteristics of study participants according to vitamin D status

  Variable                          Vitamin D deficient group (n=116)   Vitamin D insufficient group (n=118)   Vitamin D sufficient group (n=68)   *P*
  --------------------------------- ----------------------------------- -------------------------------------- ----------------------------------- ---------
  Anthropometric parameter                                                                                                                         
   Age (yr)                         59.1±15.8                           55.3±16.1                              59.9±15.6                           0.390
   Male sex (%)                     23.5                                48.8                                   43.2                                0.070
   BMI (kg/m^2^)                    24.4±4.0                            24.8±4.2                               25.2±3.8                            0.378
   Hypertension (%)                 47.1                                41.5                                   59.5                                0.378
   SBP (mmHg)                       123.8±15.6                          128.1±17.1                             123.9±16.6                          0.431
   DBP (mmHg)                       72.5±11.1                           78.0±10.9                              75.2±10.7                           0.096
   Duration of diabetes (yr)        8.0±10.6                            6.8±5.6                                7.1±6.3                             0.782
                                                                                                                                                   
  Biochemical metabolic parameter                                                                                                                  
   25(OH)D (ng/mL)                  7.0±2.3                             14.6±2.8                               30.9±10.9                           \<0.001
   FPG (mg/dL)                      185.5±69.9                          162.5±66.5                             209.8±120.5                         0.593
   HbA1c (%)                        9.4±1.9                             10.5±2.4                               10.6±3.4                            0.136
   Total cholesterol (mg/dL)        173.0±50.2                          172.2±59.9                             168.1±73.9                          0.937
   Triglyceride (mg/dL)             166.1±161.8                         166.3±104.2                            178.3±138.5                         0.907
   HDL cholesterol (mg/dL)          39.8±47.1                           35.4±43.9                              35.5±41.9                           0.178
   LDL cholesterol (mg/dL)          88.9±117.2                          87.4±124.2                             78.2±95.6                           0.133
   AST (IU/L)                       28.0±25.0                           24.9±16.2                              22.2±13.1                           0.227
   ALT (IU/L)                       31.5±33.6                           31.9±26.3                              27.7±24.9                           0.677
   Creatinine (mg/dL)               1.2±0.6                             1.4±1.1                                1.2±0.4                             0.300
   Fasting insulin (μIU/mL)         7.6±6.7                             9.8±7.3                                12.6±12.5                           0.103
   Fasting C-peptide (ng/mL)        2.1±1.4                             2.9±2.0                                3.6±3.5                             0.037
   HOMA-IR                          4.4±5.4                             2.5±2.1                                3.6±3.1                             0.112
  Treatment modality                                                                                                                               0.032
   No treatment (%)                 23.5                                25.7                                   22.2                                
   OHA (%)                          35.3                                34.3                                   36.1                                
   Insulin (%)                      35.3                                20.0                                   22.2                                
   OHA+insulin (%)                  5.9                                 17.1                                   19.4                                

Values are presented as mean±standard deviation. Chi-square test was used to compare sex, hypertension, and treatment modality.

Vitamin D deficient group, 25(OH)D \<10 ng/mL; Vitamin D insufficient group, 10 ng/mL≤ 25(OH)D \<20 ng/mL; Vitamin D sufficient group, 25(OH)D ≥20 ng/mL; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D, 25-hydroxyvitamin D; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance; OHA, oral hypoglycemic agent.

###### 

Correlations between vitamin D levels and clinical and biochemical variables

  Variable                     25(OH)D   
  ---------------------------- --------- ---------
  Age (yr)                     0.117     0.111
  BMI (kg/m^2^)                0.118     0.113
  SBP (mmHg)                   0.062     0.011
  DBP (mmHg)                   0.037     0.351
  Duration of diabetes (yr)    0.019     0.421
  FPG (mg/dL)                  0.087     0.186
  HbA1c (%)                    0.052     0.294
  Total cholesterol (mg/dL)    −0.097    0.234
  Triglyceride (mg/dL)         −0.006    0.475
  HDL cholesterol (mg/dL)      −0.155    0.053
  LDL cholesterol (mg/dL)      −0.150    0.061
  AST (IU/L)                   −0.119    0.162
  ALT (IU/L)                   −0.085    0.319
  Creatinine (mg/dL)           −0.069    0.234
  Fasting insulin (μIU/mL)     0.235      0.010 
  Fasting C-peptide (ng/mL)    0.287     0.002
  HOMA-IR                      −0.264    0.112

25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance.

###### 

Multivariate logistic regression analysis with the presence and absence of NAFLD as the dependent variable

  Variable           Odds ratio (95% CI)    *P*
  ----------------- ----------------------- ---------
  Age               0.968 (0.935--1.003)     0.071 
                                            
  Sex (male)        0.780 (0.302--2.011)    0.606
                                            
  BMI               1.156 (1.017--1.313)    0.026
                                            
  HbA1c             1.007 (0.858--1.182)    0.930
                                            
  25(OH)D (ng/mL)                           
   \<10             1                       
   ≥10 & \<20       0.244 (0.075--0.793)    0.019
   ≥20              0.109 (0.035--0.342)    \<0.001
                                            
  HOMA-IR           1.072 (0.935--1.230)    0.317

NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; BMI, body mass index; HbA1c, glycated hemoglobin; 25(OH)D, 25-hydroxyvitamin D; HOMA-IR, homeostasis model assessment of insulin resistance.
